N/A
Completed N=48
SMART Effectiveness Trial
Opioid Use Disorder · opioid dependence · Treatment Adherence
Source: ClinicalTrials.gov NCT04464421 ↗
Enrolled (actual)
48
Serious AEs
4.6%
Results posted
Sep 2022
Primary outcomePrimary: Treatment Adherence — 16; 13 Participants
Summary
The current study piloted two psychosocial interventions developed to increase buprenorphine-naloxone adherence in individuals with opioid use disorder (OUD). Participants were randomized to receive either contingency management (CM) or a brief substance free activities session plus mindfulness (BSM) cognitive-behavioral intervention. Participants were 48 newly presenting patients from an OUD treatment clinic. The primary outcome was medication adherence, as measured by buprenorphine metabolite in urine and presence at 2 or more of 4 possible physician visits.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Adherence |
16; 13 | — |
Eligibility Criteria
Inclusion Criteria
- Present for an intake appointment at study site for treatment of opioid use disorder.
- Eligible for receipt of buprenorphine-naloxone treatment (e.g. Suboxone, Bunavil, Zubsolv) as determined by clinic physicians
- 18 years or older
- Willing to be randomized to one of the two intervention arms
- Ability to comprehend consent and intervention materials (approximately 8th-grade level).
Data sourced from ClinicalTrials.gov (NCT04464421). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.